↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Gulacsi L) "

Search: WFRF:(Gulacsi L)

Result 1-7 of 7

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Ersek, K, et al. (author) Costs of dementia in Hungary 2010 In: The journal of nutrition, health & aging. - : Springer Science and Business Media LLC. - 1760-4788 .- 1279-7707. ; 14:8, s. 633-639 Journal article (peer-reviewed)
2.	Pentek, M, et al. (author) Characteristics of rheumatoid arthritis patients in Hungary - Burden of the disease 2005 In: ANNALS OF THE RHEUMATIC DISEASES. - 0003-4967. ; 64, s. 405- Conference paper (other academic/artistic)
3.	Wimo, A, et al. (author) The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project 2011 In: International journal of geriatric psychiatry. - : Wiley. - 1099-1166 .- 0885-6230. ; 26:8, s. 825-832 Journal article (peer-reviewed)
4.	Genet, N, et al. (author) Current trends and challenges and how they are dealt with. 2010 In: Journal of Clinical Nursing. - : Wiley-Blackwell. ; , s. 48-49 Conference paper (peer-reviewed)
5.	Genet, N, et al. (author) Human resources in home care in Europe. 2010 In: Journal of Clinical Nursing. - : Wiley-Blackwell. Conference paper (peer-reviewed)
6.	Genet, N, et al. (author) Integrating home care services in Europe. 2010 In: Journal of Clinical Nursing. - : Wiley-Blackwell. Conference paper (peer-reviewed)
7.	Rencz, Fanni, et al. (author) Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe 2017 In: Expert review of pharmacoeconomics & outcomes research. - : Taylor & Francis. - 1473-7167 .- 1744-8379. ; 17:6, s. 597-606 Journal article (peer-reviewed)abstract BACKGROUND: This study aims to compare the cost-effectiveness of treatment sequences with available biologics, including adalimumab (ADA), biosimilar infliximab (bsIFX), originator infliximab (IFX) and vedolizumab (VEDO) for luminal Crohn's disease in nine European countries.METHODS: A Markov-model was constructed to simulate five-year medical costs and quality-adjusted life years (QALYs). Data on clinical efficacy were obtained from randomised controlled trials. Country-specific unit costs, discount rates and a third-party payer perspective were applied.RESULTS: The bsIFX versus conventional therapy resulted in the most favourable incremental cost-utility ratios (ICURs) ranging from €34,580 (Hungary) to €77,062/QALY (Sweden). Compared to bsIFX, the bsIFX-ADA sequence was more cost-effective than the bsIFX-VEDO sequence with ICURs varying between €70,277 (France) and €162,069/QALY (Germany). The ICURs of the bsIFX-ADA-VEDO sequence versus the bsIFX-ADA strategy were between €206,266 (The Netherlands) and €363,232/QALY (Spain).CONCLUSION: We are the first to compare cost-effectiveness of multiple biological sequences for luminal Crohn's disease. Based on our findings, bsIFX can be recommended as a first-line treatment in patients unresponsive to conventional treatments. While biological sequences only slightly differ in their associated health gains, their costs vary greatly. The bsIFX-ADA-VEDO seems to be the most cost-effective sequence of the available biologics across Europe.

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-7 of 7

Refine your search

Type of publication: conference paper (4); journal article (3)

Type of content: peer-reviewed (6); other academic/artistic (1)

Author/Editor: Gulacsi, L (6); Ersek, K (5); Hutchinson, A (3); Lamura, G (3); Fagerström, Cecilia (3); Boerma, W (3); show more...; Garms-Homolova, V (3); Genet, N (3); Naiditch, M (3); Chablicz, S (3); Jonsson, L. (2); Gustavsson, A. (2); Wimo, A (2); McDaid, D (2); Karpati, K (2); Pentek, M (2); Valtonen, H (2); Gomollon, Fernando (1); Halfvarson, Jonas, 1 ... (1); Szekanecz, Z. (1); Poor, G. (1); Czirjak, L (1); Kobelt, G (1); Dignass, Axel (1); Kovács, T (1); Georges, J (1); Péntek, Márta (1); Majer, I. (1); Lakatos, Peter L (1); Peyrin-Biroulet, Lau ... (1); Gecse, Krisztina B. (1); Brodszky, V (1); Kenigsberg, PA (1); Gulàcsi, László (1); Rojkovich, B (1); Genti, G (1); Polgar, A (1); Lepp-Gazdag, A (1); Brodszky, Valentin (1); Baji, Petra (1); Rencz, Fanni (1); Kenigsberg, P (1); show less...

University: Karolinska Institutet (3); Blekinge Institute of Technology (3); Örebro University (1)

Language: English (7)

Research subject (UKÄ/SCB): Medical and Health Sciences (4); Social Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view